NCE-1 Intelligence & Market Opportunity

Nulibry

Fosdenopterin

Antimetabolic disorder

Intravenous Powder

Approval Date

26-Feb-21

NCE-1 Date

26-Feb-25

NCE Date

26-Feb-26

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Fosdenopterin

Innovator

SENTYNL THERAPEUTICS, INC.

Dosage Form

Intravenous Powder

Strength

EQ 9.5 mg base/vial

Therapeutic Category

Antimetabolic disorder

Usage

To reduce the risk of mortality in molybdenum cofactor deficiency Type A

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.